- Home
- EYEN vs PSNL Comparison
EYEN vs PSNL Comparison
Compare EYEN & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- PSNL
- Stock Information
- Founded
- EYEN 2014
- PSNL 2011
- Country
- EYEN United States
- PSNL United States
- Employees
- EYEN N/A
- PSNL N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- PSNL Medical Specialities
- Sector
- EYEN Health Care
- PSNL Health Care
- Exchange
- EYEN Nasdaq
- PSNL Nasdaq
- Market Cap
- EYEN 38.2M
- PSNL 321.1M
- IPO Year
- EYEN 2018
- PSNL 2019
- Fundamental
- Price
- EYEN $0.55
- PSNL $5.19
- Analyst Decision
- EYEN Strong Buy
- PSNL Strong Buy
- Analyst Count
- EYEN 2
- PSNL 4
- Target Price
- EYEN $12.00
- PSNL $6.81
- AVG Volume (30 Days)
- EYEN 879.0K
- PSNL 439.4K
- Earning Date
- EYEN 11-11-2024
- PSNL 11-06-2024
- Dividend Yield
- EYEN N/A
- PSNL N/A
- EPS Growth
- EYEN N/A
- PSNL N/A
- EPS
- EYEN N/A
- PSNL N/A
- Revenue
- EYEN $31,405.00
- PSNL $80,027,000.00
- Revenue This Year
- EYEN $50,309.30
- PSNL $10.85
- Revenue Next Year
- EYEN $421.63
- PSNL $8.77
- P/E Ratio
- EYEN N/A
- PSNL N/A
- Revenue Growth
- EYEN N/A
- PSNL 19.20
- 52 Week Low
- EYEN $0.37
- PSNL $0.89
- 52 Week High
- EYEN $2.57
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- EYEN 52.60
- PSNL 56.29
- Support Level
- EYEN $0.52
- PSNL $4.54
- Resistance Level
- EYEN $0.59
- PSNL $5.35
- Average True Range (ATR)
- EYEN 0.05
- PSNL 0.30
- MACD
- EYEN 0.01
- PSNL 0.05
- Stochastic Oscillator
- EYEN 66.45
- PSNL 84.71
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.